Get the Stockscreener App
4.85
2.32%
0.11
Pre-market:
4.85
Cvrx Inc stock is traded at $4.85, with a volume of 391.96K.
It is up +2.32% in the last 24 hours and down -6.91% over the past month.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
See More
Previous Close:
$4.74
Open:
$4.78
24h Volume:
391.96K
Relative Volume:
1.41
Market Cap:
$127.61M
Revenue:
$47.26M
Net Income/Loss:
$-58.48M
P/E Ratio:
-1.793
EPS:
-2.7049
Net Cash Flow:
$-40.45M
1W Performance:
-20.23%
1M Performance:
-6.91%
6M Performance:
-29.40%
1Y Performance:
-67.62%
1-Day Range:
$4.43
$4.939
1-Week Range:
$4.3701
$6.22
52-Week Range:
$4.2993
$15.00
Cvrx Inc Stock (CVRX) Company Profile
Name
Cvrx Inc
Sector
Industry
Phone
(763) 416-2850
Address
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
4.85 | 124.72M | 47.26M | -58.48M | -40.45M | -2.7049 |
|
ABT
Abbott Laboratories
|
113.29 | 195.21B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
377.32 | 141.28B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
98.49 | 123.60B | 35.48B | 4.64B | 5.41B | 3.5856 |
|
BSX
Boston Scientific Corp
|
76.28 | 113.14B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
78.98 | 45.52B | 6.07B | 1.06B | 799.60M | 1.8527 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-09-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-14-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-10-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-24 | Reiterated | Lake Street | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| May-01-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Lake Street | Buy |
| Jul-18-22 | Initiated | Craig Hallum | Buy |
| Jul-26-21 | Initiated | Canaccord Genuity | Buy |
| Jul-26-21 | Initiated | Piper Sandler | Overweight |
| Jul-26-21 | Initiated | William Blair | Outperform |
View All
Cvrx Inc Stock (CVRX) Latest News
Cantor Fitzgerald Upgrades CVRx (NASDAQ:CVRX) to Strong-Buy - MarketBeat
Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc.CVRX - marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beta Bionics, Inc. - GlobeNewswire Inc.
Short Interest in CVRx, Inc. (NASDAQ:CVRX) Increases By 23.4% - MarketBeat
Why CVRx Inc. stock remains on buy listsAnalyst Downgrade & Long Hold Capital Preservation Plans - mfd.ru
CVRx Inc (CVRX) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic Expansions Amid ... By GuruFocus - Investing.com Canada
Analysts Are Updating Their CVRx, Inc. (NASDAQ:CVRX) Estimates After Its Full-Year Results - Yahoo Finance
Piper Sandler Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
CCORF Maintains CVRx Inc(CVRX.US) With Buy Rating, Cuts Target Price to $10 - 富途牛牛
Why CVRx Inc. stock is favored by top institutionsJuly 2025 Recap & Expert Approved Trade Ideas - mfd.ru
CVRx Earnings Call: Investing Heavily for Future Growth - The Globe and Mail
Canaccord Genuity lowers CVRx stock price target to $10 on sector multiple decline By Investing.com - Investing.com Australia
Canaccord Genuity lowers CVRx stock price target to $10 on sector multiple decline - Investing.com Nigeria
CVRx, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
CVRx, Inc. SEC 10-K Report - TradingView
CVRx revenue up 4% to USD 16M in Q4 2025 - Medical Buyer
CVRx (CVRX) Q3 Loss Near US$12.9 Million Reinforces Profitability Concerns Despite Growth Narratives - Sahm
CVRx Q4 2025 Earnings Call Transcript - MarketBeat
CVRx Q4 2025 Earnings Call Insights - Intellectia AI
CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results - The Globe and Mail
Responsive Playbooks and the CVRX Inflection - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc.CVRX - PR Newswire
CVRx (CVRX) Q4 2025 Earnings Call Transcript - AOL.com
CVRx Q4 Earnings Call Highlights - MarketBeat
CVRX: Revenue and margin growth set the stage for accelerated expansion with new reimbursement and clinical trial catalysts - TradingView
CVRx earnings missed by $0.02, revenue topped estimates - Investing.com Canada
CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings call transcript: CVRx Q4 2025 sees stock surge despite earnings miss - Investing.com
CVRx (NASDAQ:CVRX) Announces Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat
CVRx: Q4 Earnings Snapshot - kare11.com
CVRx: Fourth Quarter Financial Highlights - Bitget
What’s the beta of CVRx Inc. stockOil Prices & Weekly Setup with High ROI Potential - mfd.ru
Can CVRx Inc. stock deliver consistent earnings growthJuly 2025 News Drivers & AI Enhanced Trade Execution Alerts - mfd.ru
Will CVRX benefit from government policyJuly 2025 News Drivers & Fast Moving Stock Watchlists - mfd.ru
CVRx's Earnings: A Preview - Benzinga
Can CVRx Inc. expand into new markets2025 Growth vs Value & AI Driven Stock Reports - mfd.ru
CVRX INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving CVRx Inc. - Business Wire
Does CVRx Inc. meet Warren Buffett’s criteria2025 Valuation Update & Long Hold Capital Preservation Plans - mfd.ru
CVRX Stock Price and Chart — NASDAQ:CVRX - TradingView
CVRx, Inc. (NASDAQ:CVRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
CVRx showcases Barostim integration at heart failure program - Traders Union
Growth Value: Should you buy the dip on CVRx IncJuly 2025 Retail & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Returns Recap: Whats the beta of CVRx Inc stockJuly 2025 Review & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
S P Trends: Whats the beta of CVRx Inc stockJuly 2025 Retail & Daily Profit Maximizing Tips - baoquankhu1.vn
Income Plays: How correlated is CVRX to the S P5002025 Trading Recap & Verified Entry Point Signals - baoquankhu1.vn
Understanding the Setup: (CVRX) and Scalable Risk - Stock Traders Daily
CVRx ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
CVRx ALERT: Bragar Eagel & Squire, P.C. is Investigating CVRx Inc. on Behalf of CVRx Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026 - Sahm
CVRx INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud - Business Wire
Cvrx Inc Stock (CVRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):